Form 6-K NOVO NORDISK A S For: May 06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

May 6, 2022

________________

 

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

 

 

Novo Allé 

DK- 2880, Bagsvaerd 

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F [X]

Form 40-F [  ]

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes [  ]

No [X]

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________

 

 

 

 

 

 

Novo Nordisk – major shareholder announcement

 

Bagsværd, Denmark, 6 May 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 29 April 2022 holds B shares equal to 5.06% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act.

 

The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to 5.07% of the entire share capital and below 5% of the voting rights.

 

For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annex.

 

 

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). or more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

 

 

 

Further information

Media:
Ambre Brown Morley	+45 3079 9289	[email protected]
Natalia Salomao Abrahao (US)	+1 848 304 1027	[email protected]
Investors:
Daniel Muusmann Bohsen	+45 3075 2175	[email protected]
Ann Søndermølle Rendbæk	+45 3075 2253	[email protected]
David Heiberg Landsted	+45 3077 6915	[email protected]
Jacob Martin Wiborg Rode	+45 3075 5956	[email protected]
Mark Joseph Root (US)	+1 848 213 3219	[email protected]

 

 

 

Annex: Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity as of 3 May 2022

 

Name	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
BlackRock Japan Co., Ltd.			Below 5%
BlackRock Investment Management, LLC			Below 5%
BlackRock Investment Management (UK) Limited			Below 5%
BlackRock Investment Management (Australia) Limited			Below 5%
BlackRock International Limited			Below 5%
BlackRock Institutional Trust Company, National Association			Below 5%
BlackRock Fund Advisors			Below 5%
BlackRock Financial Management, Inc.			Below 5%
BlackRock Asset Management North Asia Limited			Below 5%
BlackRock Asset Management Deutschland AG			Below 5%
BlackRock Asset Management Canada Limited			Below 5%
BlackRock Advisors, LLC			Below 5%
BlackRock Advisors (UK) Limited			Below 5%
BlackRock (Singapore) Limited			Below 5%
BlackRock Asset Management Ireland Limited			Below 5%
Aperio Holdings, LLC			Below 5%

 

 

 

Novo Nordisk A/S Investor Relations	Novo Allé 2880 Bagsværd Denmark	Telephone: +45 4444 8888	Internet: www.novonordisk.com CVR no: 24 25 67 90
		Company announcement No 44 / 2022

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: May 6, 2022

NOVO NORDISK A/S   Lars Fruergaard Jørgensen Chief Executive Officer

 

 

 

 

 

 

 

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Threshold to make it into the Top 100 biggest global companies is now at $141B - report
• Form 8.3 - Mattioli Woods plc
• Ameresco Announces the Installation of Energy-Efficient Solar Arrays in Partnership with Wakefield Municipal Gas & Light